1. Vorster MJ, Allwood BW, Diacon AH, Koegelenberg CF. Tuberculous pleural effusions: advances and controversies. J Thorac Dis 2015; 7: 981-991.
2. Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2015; 59: 4129-4138..
3. Rullas J, Dhar N, McKinney JD, Garcia-Perez A, Lelievre J, Diacon AH, Hugonnet JE, Arthur M, Angulo-Barturen I, Barros-Aguirre D, Ballell L. Combinations of beta-lactam antibiotics currently in clinical trials are efficacious in a DHP-I deficient mice model of TB infection. Antimicrob Agents Chemother 2015.
4. Karinja MN, Esterhuizen TM, Friedrich SO, Diacon AH. Sputum Volume Predicts Sputum Mycobacterial Load during the First 2 Weeks of Antituberculosis Treatment. J Clin Microbiol 2015; 53: 1087-1091.
5. Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH, on behalf of the Pan African Consortium for the Evaluation of Antituberculosis A. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 2015.
6. Donald PR, Diacon AH. Para-aminosalicylic acid: the return of an old friend. Lancet Infect Dis 2015.
7. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Hutchings J, Burger DA, Schall R, Mendel CM. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015; 191: 943-953.
8. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015.
9. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE, Pan AC. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015; 191: 1058-1065.
10. Solomons RS, Visser DH, Friedrich SO, Diacon AH, Hoek KG, Marais BJ, Schoeman JF, van Furth AM. Improved diagnosis of childhood tuberculous meningitis using more than one nucleic acid amplification test. Int J Tuberc Lung Dis 2015; 19: 74-80.
11. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Eisenach K, Miller P, Diacon AH. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PloS one 2014; 9: e94462.
12. Streicher EM, Maharaj K, York T, Van Heerden C, Barnard M, Diacon A, Mendel CM, Bosman ME, Hepple JA, Pym AS, Warren RM, van Helden PD. Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility. J Clin Microbiol 2014; 52: 4056-4057.
13. Kibleur Y, Brochart H, Schaaf HS, Diacon AH, Donald PR. Dose regimen of para-aminosalicylic acid gastro- resistant formulation (PAS-GR) in multidrug-resistant tuberculosis. Clinical drug investigation 2014; 34: 269-276.
14. Karinja MN, Esterhuizen TM, Friedrich SO, Diacon AH. Sputum volume predicts sputum mycobacterial load during the first two weeks of anti-tuberculosis treatment. J Clin Microbiol 2014.
15. Diacon AH, van der Merwe L, Demers AM, Von Groote-Bidlingmaier F, Venter A, Donald PR. Pre-treatment mycobacterial sputum load influences individual on-treatment measurements. Tuberculosis (Edinb) 2014; 94: 690- 694.
16. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, Group TCS. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
17. Diacon AH, Donald PR. The early bactericidal activity of antituberculosis drugs. Expert review of anti-infective therapy 2014; 12: 223-237.
18. de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 2014; 58: 6242-6250.
19. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2013;1:462-70
20. Diacon AH, van der Merwe L, Demers AM, von Groote-Bidlingmaier F, Venter A, Donald PR. Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens. Tuberculosis (Edinb). 2014;94:148-51.
21. Kolwijck E, Friedrich SO, Karinja MN, van Ingen J, Warren RM, Diacon AH. Early stationary phase culture supernatant accelerates growth of sputum cultures collected after inititation of anti-tuberculosis treatment. J Clin Microbiol 2013;51:1094-1098
22. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM. Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis. Antimicrob Agents Chemother 2013;57:2199-2203
23. Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS 2013;8:579-585
24. Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ, Heinrich N, Hoelscher M, Diacon AH. Direct Comparison of Xpert MTB/RIF Assay with Liquid and Solid Mycobacterial Culture for Quantification of Early Bactericidal Activity. J Clin Microbiol. 2013;51:1894-8.
25. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother. 2013;57:2199-203.
26. Kolwijck E, Mitchell M, Venter A, Friedrich SO, Dawson R, Diacon AH. Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies. J Clin Microbiol. 2013;51:1094-8.
27. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012. 380:986-993.
28. Diacon AH, von Groote-Bidlingmaier F, Donald PR. From magic mountain to table mountain. Swiss Med Wkly. 2012 Aug 22
29. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. A phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012 Mar 19.
30. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, Mc Neeley DF. Randomized pilot trial of 8 weeks of bedaquiline (TMC207) for MDR-TB: long-term outcome, tolerability and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012 Mar 5.
31. Friedrich SO, von Groote-Bidlingmaier F, Diacon AH. Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. J Clin Microbiol. 2011 Dec;49(12):4341-2. Epub 2011 Oct 12.
32. Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect. 2011 Jun 30.
33. Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb). 2012 Jan;92(1):1-8.
34. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54.
35. Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol. 2011 Aug;49(8):2827-31.
36. Donald PR, Maritz JS, Diacon AH. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. Tuberculosis (Edinb). 2011 May;91(3):196-207.
 37. Diacon AH, Maritz JS, Venter A, van Helden PD, Andries K, McNeeley DF, Donald PR. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1561-5. Epub 2010 Sep 4.
38. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK. Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients. Antimicrob Agents Chemother. 2010 May 24

39. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012. 380:986-993.

40. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. A phase II dose-ranging trial of the early bactericidal activity of PA-824. AntimicrobAgents Chemother. 2012 Mar 19.

41. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF Randomized pilot trial of 8 weeks of bedaquiline (TMC207) for MDR-TB: long-term outcome, tolerability and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012 Mar 5.

42. Friedrich SO, von Groote-Bidlingmaier F, Diacon AH. Xpert MTB/RIF assay for diagnosis of pleural tuberculosis. J Clin Microbiol. 2011 Dec;49(12):4341-2. Epub 2011 Oct 12.

43. Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect. 2011 Jun 30.

44. Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb). 2012 Jan;92(1):1-8.

45. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011Jul;15(7):949-54.

46. Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol. 2011 Aug;49(8):2827-31.

47. Donald PR, Maritz JS, Diacon AH. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. Tuberculosis (Edinb). 2011 May;91(3):196-207.

48.Diacon AH, Maritz JS, Venter A, van Helden PD, Andries K, McNeeley DF, Donald PR.Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1561-5. Epub 2010 Sep 4.

49.Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK. Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients. Antimicrob Agents Chemother. 2010 May 24

50. Diacon AH, Pym A, Grobusch M, Patient ia R, Rustomjee R, et al. The diarylquinoline TMC207 for multidrug -resistant tuberculosis. N Engl J Med. 2009;360:2397-405.

51.Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: aliterature review. Tuberculosis (Edinb). 2008 Aug;88 Suppl 1:S75-83.

52. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, DeMarez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF.Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 intreatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008 Aug;52:2831-5.

53.Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother.2007;51:2994-6.

54. Direct comparison of Xpert MTB/RIF with liquid and solid mycobacterial culture for the quantification of early bactericidal activity. Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ, Heinrich N,Hoelscher M, Diacon AH; On behalf of the Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA).J Clin Microbiol. 2013 Apr 17. [Epub ahead of print]

55. Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis.

Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie. A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM. Antimicrob Agents Chemother. 2013 May;57(5):2199-203.

56. Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies.

Kolwijck E, Mitchell M, Venter A, Friedrich SO, Dawson R, Diacon AH.J Clin Microbiol. 2013 Apr;51(4):1094-8.

57. Rapid diagnosis of pediatric intrathoracic tuberculosis from stool samples using the Xpert MTB/RIF Assay: a pilot study.

Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP. Pediatr Infect Dis J. 2012 Dec;31(12):1316.

58. Para-aminosalicylic Acid plasma concentrations in children in comparison with adults after receiving a granular slow – release preparation.

Liwa AC, Schaaf HS, Rosen kranz B, Seifart HI, Diacon AH, Donald PR. J Trop Pediatr. 2013 Apr;59(2):904.

59. From magic mountain to table mountain. Diacon AH, von Groote-Bidlingmaier F, Donald PR. Swiss Med Wkly. 2012 Aug 22;142:w13665.

60.The yield of different pleural fluid volumes for Mycobacterium tuberculosis culture.

von Groote-Bidlingmaier F, Koegelenberg CF, Bolliger CT, Chung PK, Rautenbach C, Wasserman E, Bernasconi M, Friedrich SO, Diacon AH. Thorax. 2013 Mar;68(3):290-1.

 Further can be found here: